Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8877019,central compartment apparent volume of distribution,The higher concentrations were the result of the 30 to 40% smaller central compartment apparent volume of distribution that was observed in the elderly subjects as compared with the young volunteers (2.8 +/- 1.1 vs 3.9 +/- 1.11 kg-1 for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),1/[kg],2.8,346,DB00704,Naltrexone
,8877019,central compartment apparent volume of distribution,The higher concentrations were the result of the 30 to 40% smaller central compartment apparent volume of distribution that was observed in the elderly subjects as compared with the young volunteers (2.8 +/- 1.1 vs 3.9 +/- 1.11 kg-1 for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),1/[kg],3.9,347,DB00704,Naltrexone
,8877019,distributional half-life (t1/2 lambda 1),The elderly volunteers also had a significantly shorter distributional half-life (t1/2 lambda 1) than young volunteers (0.7 +/- 0.7 vs 1.3 +/- 0.8 h for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),h,0.7,348,DB00704,Naltrexone
,8877019,distributional half-life (t1/2 lambda 1),The elderly volunteers also had a significantly shorter distributional half-life (t1/2 lambda 1) than young volunteers (0.7 +/- 0.7 vs 1.3 +/- 0.8 h for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),h,1.3,349,DB00704,Naltrexone
,827709,binding to,"Studies on naltrexone disposition indicate that (a) binding to plasma proteins in several species varies from 20-26 per cent, (b) distribution of drug from blood is extremely rapid and extensive, (c) beta-naltrexol is a major metabolite of naltrexone in man, monkey and guinea pig among six species studied, whereas alpha-naltrexol is a minor metabolite in the monkey and guinea pig only, and (d) metabolic reduction of naltrexone occurs in the 100,000 x g supernatant of guinea pig liver.",Testing of drug delivery systems for use in the treatment of narcotic addiction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/827709/),%,20-26,4399,DB00704,Naltrexone
,23001479,latency,"In the second study, similar hyperalgesic responses were observed in mice lacking the multidrug resistance protein 3 (MRP3) transporter protein (Mrp3(-/-) mice) in the liver and their wild-type controls (FVB mice; latency reductions: 3.1 ± 0.2 s at t = 30 min, P < 0.001 versus within-strain baseline).",Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23001479/),s,3.1,8469,DB00704,Naltrexone
,8491826,signal-to-noise ratio,A signal-to-noise ratio of 4.5 is obtained when a 1 ng/ml spiked plasma sample is analyzed.,Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491826/),,4.5,11810,DB00704,Naltrexone
,15054115,K(i),"In a radioligand binding assay, DiPOA inhibited [(3)H]-diprenorphine binding to recombinant human mu receptors with a K(i) value of approximately 0.8 nM.","DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15054115/),nM,0.8,13758,DB00704,Naltrexone
,15054115,EC(50),"DiPOA showed potent agonist effects in a human mu receptor guanosine 5'-O-(3-[(35)S]thio)triphosphate functional assay, with an EC(50) value of approximately 33 nM and efficacy of approximately 85% [normalized to the mu agonist, [d-Ala2,MePhe4,Gly(ol)5]enkephalin].","DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15054115/),nM,33,13759,DB00704,Naltrexone
<,15054115,central nervous system penetration,"High and sustained (> or =5 h) plasma levels for DiPOA were achieved following intraperitoneal administration at 3 and 10 mg/kg; central nervous system penetration, however, was < or =4% of the plasma concentration, even at levels exceeding 1500 ng/ml.","DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15054115/),,4,13760,DB00704,Naltrexone
,6114837,terminal plasma half-life,"The route of administration significantly affected terminal plasma half-life values obtained for unconjugated naltrexone (2.7 hr, iv; 8.9 hr, oral), but had little effect on comparable values obtained for total drug, conjugated naltrexone, and unconjugated and conjugated 6 beta-naltrexol.",Metabolism and disposition of naltrexone in man after oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114837/),h,2.7,14464,DB00704,Naltrexone
,6114837,terminal plasma half-life,"The route of administration significantly affected terminal plasma half-life values obtained for unconjugated naltrexone (2.7 hr, iv; 8.9 hr, oral), but had little effect on comparable values obtained for total drug, conjugated naltrexone, and unconjugated and conjugated 6 beta-naltrexol.",Metabolism and disposition of naltrexone in man after oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114837/),h,8.9,14465,DB00704,Naltrexone
,17192502,time to maximum concentration (tmax),"Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (tmax) was 52.2 and 49.8 minutes, respectively.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),min,52.2,15845,DB00704,Naltrexone
,17192502,time to maximum concentration (tmax),"Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (tmax) was 52.2 and 49.8 minutes, respectively.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),min,49.8,15846,DB00704,Naltrexone
,17192502,Peak plasma concentration of fentanyl (Cmax),Peak plasma concentration of fentanyl (Cmax) was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen.,Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),[ng] / [ml],0.88,15847,DB00704,Naltrexone
,17192502,Peak plasma concentration of fentanyl (Cmax),Peak plasma concentration of fentanyl (Cmax) was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen.,Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),[ng] / [ml],1.77,15848,DB00704,Naltrexone
,17192502,half-life,"Steady state was reached within 5 days, consistent with the observed median half-life of approximately 22 hours following multiple doses.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),h,22,15849,DB00704,Naltrexone
,108382,total body clearance,A two-compartment open pharmacokinetic model was fitted to plasma level-time data for naltrexone in two dogs and yielded a total body clearance of 51-55 ml/min/kg.,Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/108382/),[ml] / [kg·min],51-55,16516,DB00704,Naltrexone
,108382,terminal half-life,Plasma level-time data for intravenous naltrexone in six monkeys yielded an average terminal half-life of 7.8 hr and a total body clearance of 64 ml/min/kg.,Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/108382/),h,7.8,16517,DB00704,Naltrexone
,108382,total body clearance,Plasma level-time data for intravenous naltrexone in six monkeys yielded an average terminal half-life of 7.8 hr and a total body clearance of 64 ml/min/kg.,Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/108382/),[ml] / [kg·min],64,16518,DB00704,Naltrexone
,3247293,h,The plasma (dog and human) hydrolysis half-life of 3 was found to be approximately 30 min.,Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247293/),min,30,19089,DB00704,Naltrexone
,3247293,t1/2,"Compound 2 was previously shown to hydrolyze in dog and human plasma with a fast deacetylation step to 3, followed by slower hydrolysis of 3 to 1 (t1/2, approximately 30 min).",Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247293/),min,30,19090,DB00704,Naltrexone
,3247293,half-life,The half-life of naltrexone in dogs after oral administration of 3 was similar to that observed after oral administration of 2 (approximately 1 hr).,Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247293/),h,1,19091,DB00704,Naltrexone
,15380723,flow rate,The chromatographic separation was performed on a C(18) column using a mobile phase consisting of 35:65 (v/v) acetonitrile:2 mM ammonium acetate with 0.01 mM ammonium citrate at a flow rate of 0.25 mL/min.,Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),[ml] / [min],0.25,24555,DB00704,Naltrexone
,15380723,recoveries,"The mean recoveries for naltrexone, naltrexol, and naloxone were 91.7, 89.3, and 99.0%, respectively.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),%,91.7,24556,DB00704,Naltrexone
,15380723,recoveries,"The mean recoveries for naltrexone, naltrexol, and naloxone were 91.7, 89.3, and 99.0%, respectively.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),%,89.3,24557,DB00704,Naltrexone
,15380723,recoveries,"The mean recoveries for naltrexone, naltrexol, and naloxone were 91.7, 89.3, and 99.0%, respectively.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),%,99.0,24558,DB00704,Naltrexone
,15380723,limit of detection (LOD),"The lower limit of quantification (LLOQ) for naltrexone and 6beta-naltrexol was 1.25 ng/mL, and the limit of detection (LOD) was 0.75 ng/mL.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),[ng] / [ml],0.75,24559,DB00704,Naltrexone
,19071491,limit of detection,And the limit of detection was 0.1ng/ml for naltrexone and 0.36ng/ml for 6-beta-naltrexol.,"Simultaneous analysis of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography-tandem mass spectrometry: Application to a parent-metabolite kinetic model in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071491/),[ng] / [ml],0.1,27886,DB00704,Naltrexone
,19071491,limit of detection,And the limit of detection was 0.1ng/ml for naltrexone and 0.36ng/ml for 6-beta-naltrexol.,"Simultaneous analysis of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography-tandem mass spectrometry: Application to a parent-metabolite kinetic model in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071491/),[ng] / [ml],0.36,27887,DB00704,Naltrexone
,14508328,bioavailability,Release rate estimated in vivo was similar to that measured in vitro; bioavailability did not differ from 100%.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),%,100,29506,DB00704,Naltrexone
,14508328,Absorption half-life,Absorption half-life was 16.2 h.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),h,16.2,29507,DB00704,Naltrexone
>,14508328,half-life,The rate at which sufentanil was absorbed from the subcutaneous space (half-life > 16 h) was markedly slower than reported with subcutaneous or intramuscular administration of large volumes of dilute opioids; this slow absorption dampens potential changes in Cp if release rate is perturbed.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),h,16,29508,DB00704,Naltrexone
,18321686,equivalent steady state plasma concentrations,6-Beta-naltrexol equivalent steady state plasma concentrations of 6.4 ng/ml were obtained after application of the codrug as compared to 1.2 ng/ml from 6-beta-naltrexol base.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],6.4,32584,DB00704,Naltrexone
,18321686,equivalent steady state plasma concentrations,6-Beta-naltrexol equivalent steady state plasma concentrations of 6.4 ng/ml were obtained after application of the codrug as compared to 1.2 ng/ml from 6-beta-naltrexol base.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],1.2,32585,DB00704,Naltrexone
,18321686,steady state plasma concentration,The steady state plasma concentration of hydroxybupropion after codrug application was 6.9 ng/ml.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],6.9,32586,DB00704,Naltrexone
,18062845,T(max),Median T(max) values were between 12 and 16 h and ranges were similar for all treatments.,Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062845/),h,12 and 16,34454,DB00704,Naltrexone
,25669614,AUC(0-tlast),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[h·ng] / [ml],244.422,35647,DB00704,Naltrexone
,25669614,AUC(0-tlast),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[h·ng] / [ml],246.837,35648,DB00704,Naltrexone
,25669614,AUC(0-∞),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[h·ng] / [ml],332.999,35649,DB00704,Naltrexone
,25669614,AUC(0-∞),"The geometric means of the parameters related with the extent of total exposure of levomethadone, i.e., AUC(0-tlast) and AUC(0-∞), were 244.422 ng x h/mL and 332.999 ng x h/mL for test and 246.837 ng x h/mL and 329.467 ngÃh/mL for reference, respectively.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ngãh] / [ml],329.467,35650,DB00704,Naltrexone
,25669614,peak exposure,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.923,35651,DB00704,Naltrexone
,25669614,peak exposure,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.635,35652,DB00704,Naltrexone
,25669614,Cmax,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.923,35653,DB00704,Naltrexone
,25669614,Cmax,"The geometric means of the peak exposure for levomethadone, i.e., Cmax, were 8.923 ng/mL for test and 8.635 ng/mL for reference.",Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669614/),[ng] / [ml],8.635,35654,DB00704,Naltrexone
,23936895,peak effect (Emax),"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,69.6,37015,DB00704,Naltrexone
,23936895,peak effect (Emax),"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,55.2,37016,DB00704,Naltrexone
,23936895,area under the effect curve,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,86.3,37017,DB00704,Naltrexone
,23936895,area under the effect curve,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,66.7,37018,DB00704,Naltrexone
,23936895,Emax,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,87.6,37019,DB00704,Naltrexone
,23936895,Emax,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,86.6,37020,DB00704,Naltrexone
,23936895,area under the curve over 2 h,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,120.6,37021,DB00704,Naltrexone
,23936895,area under the curve over 2 h,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,132.9,37022,DB00704,Naltrexone
,23936895,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),ng⁄ml,27.3,37023,DB00704,Naltrexone
,23936895,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),ng⁄ml,27.7,37024,DB00704,Naltrexone
,23936895,time to Cmax,"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.57,37025,DB00704,Naltrexone
,23936895,time to Cmax,"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.6,37026,DB00704,Naltrexone
,23936895,Cmax,Naltrexone mean Cmax was 1497 pg⁄mL after MSN and median time to Cmax was 0.55 h.,Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),pg⁄ml,1497,37027,DB00704,Naltrexone
,23936895,time to Cmax,Naltrexone mean Cmax was 1497 pg⁄mL after MSN and median time to Cmax was 0.55 h.,Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.55,37028,DB00704,Naltrexone
,30351180,Tmax,"3. Naldemedine was the major circulating component in plasma with a median Tmax of approximately 0.8-0.9 h and a geometric mean t1/2,z of approximately 11 h.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),h,0.8-0.9,37268,DB00704,Naltrexone
,30351180,"t1/2,z","3. Naldemedine was the major circulating component in plasma with a median Tmax of approximately 0.8-0.9 h and a geometric mean t1/2,z of approximately 11 h.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),h,11,37269,DB00704,Naltrexone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,92,37270,DB00704,Naltrexone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,57.3,37271,DB00704,Naltrexone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,34.8,37272,DB00704,Naltrexone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,85,37273,DB00704,Naltrexone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,20.4,37274,DB00704,Naltrexone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,64.3,37275,DB00704,Naltrexone
,28960888,maximum plasma concentration,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),[ng] / [ml],1.98 to 2510,37450,DB00704,Naltrexone
,28960888,maximum plasma concentration,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),[ng] / [ml],73.8 to 700,37451,DB00704,Naltrexone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,15.9,37452,DB00704,Naltrexone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,20.5,37453,DB00704,Naltrexone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,19.7,37454,DB00704,Naltrexone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,19.1,37455,DB00704,Naltrexone
,9208648,elimination half-lives,"The elimination half-lives of NTX were 78 +/- 6 min and 74 +/- 6 min, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),min,78,38826,DB00704,Naltrexone
,9208648,elimination half-lives,"The elimination half-lives of NTX were 78 +/- 6 min and 74 +/- 6 min, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),min,74,38827,DB00704,Naltrexone
,9208648,absolute bioavailability,"Although NTX could be absorbed rapidly in the dog after po administration, the plasma concentration of the parent drug was very low and its absolute bioavailability was 15.8%.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),%,15.8,38828,DB00704,Naltrexone
,9208648,elimination half-lives,"Dosing NTX intravenously and orally, the plasma levels of the conjugate were 1.3 and 23 times as high as that of the parent drug, the elimination half-lives of the glucuronide from plasma were 3.4 h and 12.6 h, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),h,3.4,38829,DB00704,Naltrexone
,9208648,elimination half-lives,"Dosing NTX intravenously and orally, the plasma levels of the conjugate were 1.3 and 23 times as high as that of the parent drug, the elimination half-lives of the glucuronide from plasma were 3.4 h and 12.6 h, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),h,12.6,38830,DB00704,Naltrexone
,9807977,basal,Serum fentanyl concentrations sufficient for analgesia (1-3 ng/mL) were attained in treatments using the E-TRANS (fentanyl) system with basal current of 100 microA for 26 hours.,"Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9807977/),,100,39804,DB00704,Naltrexone
,25456560,Tmax,"In both studies, samidorphan was rapidly absorbed, with a Tmax of 1 hour, and AUC increased with increasing dose.","Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456560/),h,1,41670,DB00704,Naltrexone
,25456560,half-life,"Samidorphan plasma levels declined in a monoexponential manner, with a half-life of ~7 to 9 hours.","Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456560/),h,7 to 9,41671,DB00704,Naltrexone
<,25456560,accumulation ratios,"Accumulation was low, with accumulation ratios <1.65.","Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456560/),,1.65,41672,DB00704,Naltrexone
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],49.2,44070,DB00704,Naltrexone
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],32.6,44071,DB00704,Naltrexone
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],28.4,44072,DB00704,Naltrexone
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],37.3,44073,DB00704,Naltrexone
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,5.9,44074,DB00704,Naltrexone
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,8.0,44075,DB00704,Naltrexone
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,1.0,44076,DB00704,Naltrexone
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],640,44077,DB00704,Naltrexone
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],600,44078,DB00704,Naltrexone
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],578,44079,DB00704,Naltrexone
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],581,44080,DB00704,Naltrexone
,9048269,elimination half-life,"Pharmacokinetic analysis revealed an elimination half-life of 117.5 minutes (+/-53.2), and a clearance of 38.8 L/hr (+/-17.4) with a methylnaltrexone dose of 0.64 mg/kg.","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048269/),min,117.5,47186,DB00704,Naltrexone
,9048269,clearance,"Pharmacokinetic analysis revealed an elimination half-life of 117.5 minutes (+/-53.2), and a clearance of 38.8 L/hr (+/-17.4) with a methylnaltrexone dose of 0.64 mg/kg.","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048269/),[l] / [h],38.8,47187,DB00704,Naltrexone
,17329173,total chromatographic run time,The method had a total chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 10-5000 pg/mL.,Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329173/),min,4.5,48170,DB00704,Naltrexone
,31028107,blood concentrations,"Steady-state maternal blood concentrations of NorBUP in dams infused with 1 or 3 mg/kg per day were comparable to values reported in pregnant humans treated with buprenorphine (1.0 and 9.6 ng/ml, respectively), suggesting a clinically relevant dosing regimen.","In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028107/),[ng] / [ml],1.0,49281,DB00704,Naltrexone
,31028107,blood concentrations,"Steady-state maternal blood concentrations of NorBUP in dams infused with 1 or 3 mg/kg per day were comparable to values reported in pregnant humans treated with buprenorphine (1.0 and 9.6 ng/ml, respectively), suggesting a clinically relevant dosing regimen.","In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028107/),[ng] / [ml],9.6,49282,DB00704,Naltrexone
,31463821,plasma clearance,"In study 1, intravenous SAM had a plasma clearance of 33.7 L/h, volume of distribution of 341 L, and elimination half-life of 7-8 h.",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),[l] / [h],33.7,51336,DB00704,Naltrexone
,31463821,volume of distribution,"In study 1, intravenous SAM had a plasma clearance of 33.7 L/h, volume of distribution of 341 L, and elimination half-life of 7-8 h.",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),l,341,51337,DB00704,Naltrexone
,31463821,elimination half-life,"In study 1, intravenous SAM had a plasma clearance of 33.7 L/h, volume of distribution of 341 L, and elimination half-life of 7-8 h.",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),h,7-8,51338,DB00704,Naltrexone
,31463821,absolute bioavailability,"SAM was well-absorbed following sublingual or oral administration and reached peak concentrations (Cmax) within 2 h, with absolute bioavailability of 71% (sublingual) and 69% (oral).",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),%,71,51339,DB00704,Naltrexone
,31463821,absolute bioavailability,"SAM was well-absorbed following sublingual or oral administration and reached peak concentrations (Cmax) within 2 h, with absolute bioavailability of 71% (sublingual) and 69% (oral).",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),%,69,51340,DB00704,Naltrexone
,27440072,MRT0-t,"The results of pharmacokinetic study indicated that a sustained release behavior could be obtained with MRT0-t (30.34 ± 12.47) h for LXT-101 and MRT0-t (2.37 ± 0.876) h for NTX, about 10 and 4 times longer than those of aqueous solution respectively.",Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27440072/),h,30.34,51626,DB00704,Naltrexone
,27440072,MRT0-t,"The results of pharmacokinetic study indicated that a sustained release behavior could be obtained with MRT0-t (30.34 ± 12.47) h for LXT-101 and MRT0-t (2.37 ± 0.876) h for NTX, about 10 and 4 times longer than those of aqueous solution respectively.",Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27440072/),h,2.37,51627,DB00704,Naltrexone
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,94,54576,DB00704,Naltrexone
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,420,54577,DB00704,Naltrexone
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,265,54578,DB00704,Naltrexone
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,80,54579,DB00704,Naltrexone
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,125,54580,DB00704,Naltrexone
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,340,54581,DB00704,Naltrexone
,10907964,initial disposition half-life (t(1/2alpha)),"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),h,0.36,57026,DB00704,Naltrexone
,10907964,terminal elimination half-life (t(1/2beta)),"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),h,8.7,57027,DB00704,Naltrexone
,10907964,clearance,"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),[l] / [h·kg],0.729,57028,DB00704,Naltrexone
,10907964,steady-state volume of distribution,"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),[l] / [kg],7.21,57029,DB00704,Naltrexone
,2340348,sensitivities,Specific and sensitive reverse-phase HPLC assays of buprenorphine and its metabolite in biological fluids were developed with sensitivities of 2-6 ng ml-1 using fluorimetric detection.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ng] / [ml],2-6,58734,DB00704,Naltrexone
,2340348,terminal rate constants,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,41.6,58735,DB00704,Naltrexone
,2340348,total body clearance,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ml] / [min],191,58736,DB00704,Naltrexone
less,2340348,half-life,"This terminal rate constant was in contrast to the less than 100 min half-life of the second exponential fitting of the less lipophilic morphine, naloxone, and naltrexone.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),min,100,58737,DB00704,Naltrexone
,2340348,apparent volumes of distribution,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58738,DB00704,Naltrexone
,2340348,Vc,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58739,DB00704,Naltrexone
,2340348,Vd,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,663,58740,DB00704,Naltrexone
,2340348,terminal half-life,"Direct IV administration of the metabolite, buprenorphine glucuronide, gave a terminal half-life of 6 h and more than 90 per cent of the systemically circulating metabolite was excreted in bile; only 10 per cent in urine.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,6,58741,DB00704,Naltrexone
,2340348,oral bioavailability,"The oral bioavailability, estimated from the areas under the buprenorphine plasma concentration-time curve following IV and oral administration of buprenorphine in the dogs, was 3-6 per cent.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),%,3-6,58742,DB00704,Naltrexone
,21831253,T(max),"After FBT administration, fentanyl was rapidly absorbed, with T(max) ranging from 20 minutes to 4 hours postdose.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),min,20,63743,DB00704,Naltrexone
,21831253,T(max),"After FBT administration, fentanyl was rapidly absorbed, with T(max) ranging from 20 minutes to 4 hours postdose.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),h,4,63744,DB00704,Naltrexone
,21831253,AUC(0-∞),"Mean AUC(0-∞) was 1.49 ng•hour/mL, and mean C(max) was 0.237 ng/mL.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),[h·ng] / [ml],1.49,63745,DB00704,Naltrexone
,21831253,C(max),"Mean AUC(0-∞) was 1.49 ng•hour/mL, and mean C(max) was 0.237 ng/mL.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),[ng] / [ml],0.237,63746,DB00704,Naltrexone
,25616210,flow rate,Elution was achieved with a mobile phase gradient varying the proportion of a water solution containing 0.1% formic acid (solvent A) and a 0.1% formic acid in methanol solution (solvent B) at a flow rate of 300 μL/min.,Simultaneous determination of the novel tyrosine kinase inhibitor meditinib and its active metabolite demethylation meditinib in monkey plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25616210/),[μl] / [min],300,68807,DB00704,Naltrexone
>,25616210,recoveries,The mean recoveries of ME and PI from plasma were >85%.,Simultaneous determination of the novel tyrosine kinase inhibitor meditinib and its active metabolite demethylation meditinib in monkey plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25616210/),%,85,68808,DB00704,Naltrexone
,16372825,time to reach maximum serum concentration (tmax),The pharmacokinetics of FEBT were characterised by an absorption phase with a median time to reach maximum serum concentration (tmax) of 0.75-0.99 hours that was consistent irrespective of dose.,Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372825/),h,0.75-0.99,68855,DB00704,Naltrexone
,15831777,oral-cecal transit time,"Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),min,101.3,71142,DB00704,Naltrexone
,15831777,oral-cecal transit time,"Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),min,82.5,71143,DB00704,Naltrexone
,15831777,Maximum observed plasma concentrations,"Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),[ng] / [ml],538,71144,DB00704,Naltrexone
,15831777,Maximum observed plasma concentrations,"Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),[ng] / [ml],675,71145,DB00704,Naltrexone
,15831777,plasma half-life,"Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),h,2.5,71146,DB00704,Naltrexone
,15831777,plasma half-life,"Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),h,2.9,71147,DB00704,Naltrexone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],93.5,71726,DB00704,Naltrexone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],191,71727,DB00704,Naltrexone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],364,71728,DB00704,Naltrexone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],88.8,71729,DB00704,Naltrexone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],181,71730,DB00704,Naltrexone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],357,71731,DB00704,Naltrexone
,28776489,t1/2,The t1/2 of MNTX was about 7.7 h.,Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),h,7.7,71732,DB00704,Naltrexone
,28776489,Cmax,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],191,71733,DB00704,Naltrexone
,28776489,Cav,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],3.79,71734,DB00704,Naltrexone
,28776489,Cav,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],182,71735,DB00704,Naltrexone
,28776489,AUCss,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],3.79,71736,DB00704,Naltrexone
,28776489,AUCss,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],182,71737,DB00704,Naltrexone
,28776489,MRT0-∞,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),h,3.56,71738,DB00704,Naltrexone
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,12,72602,DB00704,Naltrexone
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,8,72603,DB00704,Naltrexone
,14563545,Cmax,Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h.,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),[ng] / [ml],1.6 to 6.4,74743,DB00704,Naltrexone
,14563545,tmax,Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h.,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),h,0.5 to 3,74744,DB00704,Naltrexone
,14563545,terminal half-life,The terminal half-life was approximately 26 h (range 9-69).,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),h,26,74745,DB00704,Naltrexone
,14563545,times of disintegration,Median times of disintegration were similar for all doses and formulations (range 6-12 min).,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),min,6-12,74746,DB00704,Naltrexone
,9687342,half-life,"Fentanyl pharmacokinetics with either E-TRANS (fentanyl) or intravenous infusion were time-invariant over a 24-h application period, with similar mean half-life values (about 15-18 h).",Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687342/),h,15-18,76399,DB00704,Naltrexone
,15948042,steady-state plasma concentration,A mean steady-state plasma concentration of 7.1 ng/ml was obtained after the application of transdermal patches of ME-carbonate.,In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948042/),[ng] / [ml],7.1,79207,DB00704,Naltrexone
,22128878,C(max),"Following administration of FBSF doses of 200-1200 μg, mean C(max) values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19 ng/mL, respectively.","Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[ng] / [ml],0.383,82940,DB00704,Naltrexone
,22128878,C(max),"Following administration of FBSF doses of 200-1200 μg, mean C(max) values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19 ng/mL, respectively.","Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[ng] / [ml],2.19,82941,DB00704,Naltrexone
,22128878,AUC(last),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],3.001,82942,DB00704,Naltrexone
,22128878,AUC(last),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],19.17,82943,DB00704,Naltrexone
,22128878,AUC(∞),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],3.456,82944,DB00704,Naltrexone
,22128878,AUC(∞),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],20.43,82945,DB00704,Naltrexone
,18971181,Cmax,"The main pharmacokinetic parameters of nalmefene (Cmax, Tmax, T1/2, AUC0-48, and AUC0-infinity) after the single intravenous dose were 7.34-/+1.56 microg/L, 0.08 h, 12.01-/+2.20 h, 30.29-/+9.84 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),[μg] / [l],7.34,83041,DB00704,Naltrexone
,18971181,AUC0-48,"The main pharmacokinetic parameters of nalmefene (Cmax, Tmax, T1/2, AUC0-48, and AUC0-infinity) after the single intravenous dose were 7.34-/+1.56 microg/L, 0.08 h, 12.01-/+2.20 h, 30.29-/+9.84 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),h,12.01,83042,DB00704,Naltrexone
,18971181,AUC0-infinity,"The main pharmacokinetic parameters of nalmefene (Cmax, Tmax, T1/2, AUC0-48, and AUC0-infinity) after the single intravenous dose were 7.34-/+1.56 microg/L, 0.08 h, 12.01-/+2.20 h, 30.29-/+9.84 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),μg,30.29,83043,DB00704,Naltrexone
,18971181,Cav,"The steady-state pharmacokinetic parameters including the degree of fluctuation (DF), AUCss and Cav were 4.69-/+1.29, 19.64-/+6.20 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),μg,19.64,83044,DB00704,Naltrexone
,15777102,area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)],"Following a single dose of 5, 10 or 20mg, the oxymorphone IR mean area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)] 4.5, 9.1 and 20.1 microg .",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),μg,4.5,84939,DB00704,Naltrexone
,15777102,area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)],"Following a single dose of 5, 10 or 20mg, the oxymorphone IR mean area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)] 4.5, 9.1 and 20.1 microg .",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),μg,9.1,84940,DB00704,Naltrexone
,15777102,area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)],"Following a single dose of 5, 10 or 20mg, the oxymorphone IR mean area under the plasma concentration versus time curve from time zero to infinity ([AUC(infinity)] 4.5, 9.1 and 20.1 microg .",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),μg,20.1,84941,DB00704,Naltrexone
,15777102,maximum plasma concentration ([C(max)],"h/L, respectively) and maximum plasma concentration ([C(max)] 1.1, 1.9 and 4.4 microg/L, respectively) confirmed dose proportionality.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),[μg] / [l],1.1,84942,DB00704,Naltrexone
,15777102,maximum plasma concentration ([C(max)],"h/L, respectively) and maximum plasma concentration ([C(max)] 1.1, 1.9 and 4.4 microg/L, respectively) confirmed dose proportionality.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),[μg] / [l],1.9,84943,DB00704,Naltrexone
,15777102,maximum plasma concentration ([C(max)],"h/L, respectively) and maximum plasma concentration ([C(max)] 1.1, 1.9 and 4.4 microg/L, respectively) confirmed dose proportionality.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),[μg] / [l],4.4,84944,DB00704,Naltrexone
,15777102,t(max) (time to reach C(max)),"The median t(max) (time to reach C(max)) was 0.5 hours for all single doses of oxymorphone and at steady state, and the terminal elimination half-life (t(1/2)) was approximately 7.3-9.4 hours.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),h,0.5,84945,DB00704,Naltrexone
,15777102,terminal elimination half-life (t(1/2)),"The median t(max) (time to reach C(max)) was 0.5 hours for all single doses of oxymorphone and at steady state, and the terminal elimination half-life (t(1/2)) was approximately 7.3-9.4 hours.",Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777102/),h,7.3-9.4,84946,DB00704,Naltrexone
,17402725,affinities,"Indium(III) complexes, linked to the indole nitrogen of NTI by six- to nine-atom spacers, display high affinities (0.1-0.2 nM) and excellent selectivities for binding to delta sites in vitro.",Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),nM,0.1-0.2,86961,DB00704,Naltrexone
>,17402725,specific radioactivities,The [111In]-labeled complexes can be prepared in good isolated yields ( approximately 65%) with high specific radioactivities (>3300 mCi/mumol).,Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),[mci] / [μM],3300,86962,DB00704,Naltrexone
,17402725,log D7.4,"The spacers serve as pharmacokinetic modifiers, and log D7.4 values range from -2.74 to -1.79.",Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),,2.74,86963,DB00704,Naltrexone
,17402725,log D7.4,"The spacers serve as pharmacokinetic modifiers, and log D7.4 values range from -2.74 to -1.79.",Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),,1.79,86964,DB00704,Naltrexone
,8819305,terminal half-lives,5. Pharmacokinetic analysis of the rat plasma metabolite data indicated that terminal half-lives for nalmefene and nornalmefene were comparable (approximately 1 h).,"Disposition of the opioid antagonist, nalmefene, in rat and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819305/),h,1,89907,DB00704,Naltrexone
,16861093,Total systemic exposure,"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93003,DB00704,Naltrexone
,16861093,Total systemic exposure,"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93004,DB00704,Naltrexone
,16861093,AUC(0-infinity)),"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93005,DB00704,Naltrexone
,16861093,AUC(0-infinity)),"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93006,DB00704,Naltrexone
,16861093,C(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[ng] / [ml],2.7,93007,DB00704,Naltrexone
,16861093,C(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[ng] / [ml],2.2,93008,DB00704,Naltrexone
,16861093,T(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),h,1.0,93009,DB00704,Naltrexone
,16861093,T(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),h,2.0,93010,DB00704,Naltrexone
,16861093,AUC(0-Tmax'),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],810,93011,DB00704,Naltrexone
,16861093,AUC(0-Tmax'),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],1.5,93012,DB00704,Naltrexone
,16861093,AUC(0-Tmax'),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],0.8,93013,DB00704,Naltrexone
,16861093,AUC from time 0 to 1 hour,"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],1.5,93014,DB00704,Naltrexone
,16861093,T(max),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],810,93015,DB00704,Naltrexone
,16861093,T(max),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],1.5,93016,DB00704,Naltrexone
,16861093,T(max),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],0.8,93017,DB00704,Naltrexone
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],12.6,93666,DB00704,Naltrexone
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],20.7,93667,DB00704,Naltrexone
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],30.3,93668,DB00704,Naltrexone
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],41.2,93669,DB00704,Naltrexone
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],62.5,93670,DB00704,Naltrexone
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],199,93671,DB00704,Naltrexone
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],38,93672,DB00704,Naltrexone
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],2,93673,DB00704,Naltrexone
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],592,93674,DB00704,Naltrexone
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],766,93675,DB00704,Naltrexone
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],1189,93676,DB00704,Naltrexone
,6791002,total clearance,"Mean total clearance of unconjugated naltrexone was 3510 (300) ml/min, and its mean urinary clearance was 76.0 (6.8) ml/min.",Overview of human pharmacokinetics of naltrexone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),[ml] / [min],3510,95053,DB00704,Naltrexone
,6791002,urinary clearance,"Mean total clearance of unconjugated naltrexone was 3510 (300) ml/min, and its mean urinary clearance was 76.0 (6.8) ml/min.",Overview of human pharmacokinetics of naltrexone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),[ml] / [min],76.0,95054,DB00704,Naltrexone
,6791002,Fraction of dose excreted through,Fraction of dose excreted through urine was between 55 and 60%.,Overview of human pharmacokinetics of naltrexone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),%,55 and 60,95055,DB00704,Naltrexone
,6791002,Plasma curve,"Plasma curve resulting from intravenous administration contained three exponentials: 1.9 (.5)/min, 0.18 (.07)/min and 0.00106 (.00008)/min.",Overview of human pharmacokinetics of naltrexone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),1/[min],1.9,95056,DB00704,Naltrexone
,6791002,Plasma curve,"Plasma curve resulting from intravenous administration contained three exponentials: 1.9 (.5)/min, 0.18 (.07)/min and 0.00106 (.00008)/min.",Overview of human pharmacokinetics of naltrexone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),1/[min],0.18,95057,DB00704,Naltrexone
,6791002,Plasma curve,"Plasma curve resulting from intravenous administration contained three exponentials: 1.9 (.5)/min, 0.18 (.07)/min and 0.00106 (.00008)/min.",Overview of human pharmacokinetics of naltrexone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),1/[min],0.00106,95058,DB00704,Naltrexone
,6791002,Distribution volumes,"Distribution volumes were 7.6 (.7) liters, 60 (12) liters and 164 (16) liters.",Overview of human pharmacokinetics of naltrexone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),l,7.6,95059,DB00704,Naltrexone
,6791002,Distribution volumes,"Distribution volumes were 7.6 (.7) liters, 60 (12) liters and 164 (16) liters.",Overview of human pharmacokinetics of naltrexone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),l,60,95060,DB00704,Naltrexone
,6791002,Distribution volumes,"Distribution volumes were 7.6 (.7) liters, 60 (12) liters and 164 (16) liters.",Overview of human pharmacokinetics of naltrexone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),l,164,95061,DB00704,Naltrexone
,6791002,half life,The faster exponential corresponds to gastrointestinal absorption with a half life of about 1 hour.,Overview of human pharmacokinetics of naltrexone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),h,1,95062,DB00704,Naltrexone
,6469932,half-lives,"The mean half-lives for naltrexone and beta-naltrexol were approximately 4 and 12 hours, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),h,4,95201,DB00704,Naltrexone
,6469932,half-lives,"The mean half-lives for naltrexone and beta-naltrexol were approximately 4 and 12 hours, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),h,12,95202,DB00704,Naltrexone
,6469932,renal clearance,"The renal clearance of naltrexone and beta-naltrexol was approximately 127 ml/min and 283 ml/min, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),[ml] / [min],127,95203,DB00704,Naltrexone
,6469932,renal clearance,"The renal clearance of naltrexone and beta-naltrexol was approximately 127 ml/min and 283 ml/min, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),[ml] / [min],283,95204,DB00704,Naltrexone
,6469932,total systemic clearance,The total systemic clearance for naltrexone was approximately 94 L/hr.,"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),[l] / [h],94,95205,DB00704,Naltrexone
,2618077,elimination phase,with a longer elimination phase between 238 and 1320 min.,"Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618077/),min,238 and 1320,96631,DB00704,Naltrexone
,3958962,terminal elimination half-life,Pharmacokinetic analysis indicated that naltrexone has a terminal elimination half-life of 4.6 hr.,Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958962/),h,4.6,98302,DB00704,Naltrexone
,3958962,plasma ED50,Probit analysis revealed a linear plasma level-response relationship for naltrexone antagonism of morphine analgesia with a plasma ED50 of 2.1 ng/ml when plasma morphine levels average 1126 ng/ml.,Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958962/),[ng] / [ml],2.1,98303,DB00704,Naltrexone
,7657850,bioavailable,"Compared with two 100-mg MSC tablets, the 200-mg tablet was 96% bioavailable (90% confidence interval, 88.14-105.74%).",A bioequivalence study of oral controlled-release morphine using naltrexone blockade. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657850/),%,96,99193,DB00704,Naltrexone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],4.2,103138,DB00704,Naltrexone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],25.2,103139,DB00704,Naltrexone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],16.0,103140,DB00704,Naltrexone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],8.3,103141,DB00704,Naltrexone
,29309700,absolute bioavailability,The absolute bioavailability of SL buprenorphine was 45.4% (95% confidence interval = 37.8-54.3%).,The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),%,45.4,103472,DB00704,Naltrexone
,29309700,times to peak plasma concentration,"The median times to peak plasma concentration were 10 minutes and 60 minutes after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),min,10,103473,DB00704,Naltrexone
,29309700,times to peak plasma concentration,"The median times to peak plasma concentration were 10 minutes and 60 minutes after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),min,60,103474,DB00704,Naltrexone
,29309700,peak plasma concentration,"The peak plasma concentration was 2.65 ng/mL and 0.74 ng/mL after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),[ng] / [ml],2.65,103475,DB00704,Naltrexone
,29309700,peak plasma concentration,"The peak plasma concentration was 2.65 ng/mL and 0.74 ng/mL after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),[ng] / [ml],0.74,103476,DB00704,Naltrexone
,29309700,half-lives,"The half-lives were 9.1 hours and 11.2 hours after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),h,9.1,103477,DB00704,Naltrexone
,29309700,half-lives,"The half-lives were 9.1 hours and 11.2 hours after IV and SL administration, respectively.",The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29309700/),h,11.2,103478,DB00704,Naltrexone
,15842759,recovery,The mean recovery for nalmefene was 80% in human plasma.,Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),%,80,111209,DB00704,Naltrexone
,15842759,area under curve for 0 to 24 h,"Following intravenous injection of 5 mg/kg nalmefene to rabbits, the mean area under curve for 0 to 24 h was 1116 (ng)(mL)(-1)(h), and the mean plasma clearance was 67.9 (mL)(min)(-1)(kg)(-1).",Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),1/[ng)(ml],1116,111210,DB00704,Naltrexone
,15842759,plasma clearance,"Following intravenous injection of 5 mg/kg nalmefene to rabbits, the mean area under curve for 0 to 24 h was 1116 (ng)(mL)(-1)(h), and the mean plasma clearance was 67.9 (mL)(min)(-1)(kg)(-1).",Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),1/[ml)(min],67.9,111211,DB00704,Naltrexone
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.07,114342,DB00704,Naltrexone
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.82,114343,DB00704,Naltrexone
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,8,114344,DB00704,Naltrexone
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,4,114345,DB00704,Naltrexone
,30049503,peak plasma,"Both morphine ARER and ER morphine exhibited peak plasma morphine and M6G concentrations of ∼30 ng/mL and ∼200 ng/mL, respectively, at 3 hours postdose.","Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30049503/),[ng] / [ml],∼30,114639,DB00704,Naltrexone
,30049503,peak plasma,"Both morphine ARER and ER morphine exhibited peak plasma morphine and M6G concentrations of ∼30 ng/mL and ∼200 ng/mL, respectively, at 3 hours postdose.","Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30049503/),[ng] / [ml],∼200,114640,DB00704,Naltrexone
≥,33629900,trough methadone concentrations,"Compared with baseline, temperatures significantly decreased for treatment 1 group dogs at 2 to ≥ 4 hours and from 16 to ≥ 50 hours (12 hours after last dose) and for treatment 2 group dogs at 2 to ≥ 36 hours (12 hours after last dose), when trough methadone concentrations were ≥ 21.3 ng/mL.",Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629900/),[ng] / [ml],21.3,123862,DB00704,Naltrexone
,30940694,time to reach Cmax (Tmax),"Nalmefene was absorbed slowly following IN administration, with a median time to reach Cmax (Tmax) of 2 hours.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,2,126814,DB00704,Naltrexone
,30940694,Tmax,"Addition of the absorption enhancer dodecyl maltoside (Intravail, Neurelis, Inc., Encinitas, CA) reduced Tmax to 0.25 hour and increased Cmax by ∼2.2-fold.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,0.25,126815,DB00704,Naltrexone
>,30940694,half-life,"The high affinity, very rapid onset, and long half-life (>7 hours) of IN nalmefene present distinct advantages as a rescue medication, particularly against longer-lived synthetic opioids.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,7,126816,DB00704,Naltrexone
,6150815,absorption rate constant,The mean absorption rate constant was 0.091 +/- 0.008 min-1 (half-life of 7.6 min).,Naltrexone disposition in man after subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[min],0.091,127021,DB00704,Naltrexone
,6150815,half-life,The mean absorption rate constant was 0.091 +/- 0.008 min-1 (half-life of 7.6 min).,Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),min,7.6,127022,DB00704,Naltrexone
,6150815,terminal phase plasma rate constant,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[h],0.413,127023,DB00704,Naltrexone
,6150815,terminal phase plasma rate constant,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[h],0.0786,127024,DB00704,Naltrexone
,6150815,half-life,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),h,1.68,127025,DB00704,Naltrexone
,6150815,half-life,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[h],0.0786,127026,DB00704,Naltrexone
,6150815,half-life,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),h,8.8,127027,DB00704,Naltrexone
,18832863,Volume of distribution,Volume of distribution (approximately 2.5-3 l/kg) and the half-life (approximately 1 h) were similar.,"Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832863/),[l] / [kg],2.5-3,128114,DB00704,Naltrexone
,18832863,half-life,Volume of distribution (approximately 2.5-3 l/kg) and the half-life (approximately 1 h) were similar.,"Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832863/),h,1,128115,DB00704,Naltrexone
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],5.05,131968,DB00704,Naltrexone
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],5.29,131969,DB00704,Naltrexone
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],31.51,131970,DB00704,Naltrexone
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],31.23,131971,DB00704,Naltrexone
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],50.16,131972,DB00704,Naltrexone
,22162639,AUC(0-t),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[h·ng] / [ml],49.01,131973,DB00704,Naltrexone
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],0.38,131974,DB00704,Naltrexone
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],0.37,131975,DB00704,Naltrexone
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],2.37,131976,DB00704,Naltrexone
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],2.41,131977,DB00704,Naltrexone
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],5.87,131978,DB00704,Naltrexone
,22162639,C(max),"Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC(0-t) (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and C(max) (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions.",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),[ng] / [ml],5.63,131979,DB00704,Naltrexone
,22162639,Ad,"Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),,25,131980,DB00704,Naltrexone
,22162639,Ad,"Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),,23,131981,DB00704,Naltrexone
,22162639,Ad,"Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).",Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162639/),,9,131982,DB00704,Naltrexone
,20006596,K(i),SCH 486757 selectively binds human NOP receptor (K(i)=4.6+/-0.61nM) over classical opioid receptors.,Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006596/),nM,4.6,132212,DB00704,Naltrexone
,2575491,Total urinary excretion,"Total urinary excretion of NTX and metabolites after po administration was 89% of that after iv administration, suggestive of good absorption of NTX from solution.",Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575491/),%,89,136712,DB00704,Naltrexone
,2575491,extraction ratio,The calculated extraction ratio was 0.96-0.99.,Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575491/),,0.96-0.,136713,DB00704,Naltrexone
,26483076,systemic clearance,The typical subject in the population was estimated to have a systemic clearance of 60.4 l h(-1) and a central volume of distribution of 266 l.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),[l] / [h],60.4,137012,DB00704,Naltrexone
,26483076,central volume of distribution,The typical subject in the population was estimated to have a systemic clearance of 60.4 l h(-1) and a central volume of distribution of 266 l.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),l,266,137013,DB00704,Naltrexone
,26483076,Absolute oral bioavailability,Absolute oral bioavailability was estimated to 41% without food intake and with food about 53%.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),%,41,137014,DB00704,Naltrexone
,26483076,Absolute oral bioavailability,Absolute oral bioavailability was estimated to 41% without food intake and with food about 53%.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),%,53,137015,DB00704,Naltrexone
,17960304,CL,"Naltrexone CL (140 L/h) and V (38,300 L) were dependent on weight (changes of 0.548 L/h/kg and 0.655 L/kg, respectively) and were 23% and 35% higher, respectively, in subjects with alcohol and/or opioid dependence than in healthy subjects.",Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960304/),[l] / [h],140,137702,DB00704,Naltrexone
,17960304,V,"Naltrexone CL (140 L/h) and V (38,300 L) were dependent on weight (changes of 0.548 L/h/kg and 0.655 L/kg, respectively) and were 23% and 35% higher, respectively, in subjects with alcohol and/or opioid dependence than in healthy subjects.",Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960304/),l,"38,300",137703,DB00704,Naltrexone
,17960304,CL,"Naltrexone CL also was dependent on age (-0.108 L/h/year); 6beta-naltrexol CL (65.1 L/h) was dependent on creatinine CL (0.229 L/h/ml/minute) and alkaline phosphatase (-0.130 L/h/IU/L), and was increased by 18% in smokers and in alcohol- and/or opioid-dependent subjects.",Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960304/),[l] / [h],65.1,137704,DB00704,Naltrexone
,28070862,t max,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),h,4-10,138015,DB00704,Naltrexone
,28070862,t max,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),h,24,138016,DB00704,Naltrexone
,28070862,terminal half-life,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),d,19-25,138017,DB00704,Naltrexone
,28070862,terminal half-life,Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w).,Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070862/),d,5,138018,DB00704,Naltrexone
,9374341,Clearance half-times,Clearance half-times from opioid receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.,Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374341/),h,28.7,138023,DB00704,Naltrexone
,9374341,Clearance half-times,Clearance half-times from opioid receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.,Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374341/),h,2.0,138024,DB00704,Naltrexone
,32375158,half-life,"MCAM plasma concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased markedly 1 day after injection.","Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32375158/),min,13.7 to 199.8,138215,DB00704,Naltrexone
,20137766,Bioavailability,"Bioavailability compared with OTFC was significantly greater for all nasal fentanyl formulations (FPNS 132.4%, FChNS 154.1%, FChPNS 122.3%).","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),%,132.4,139717,DB00704,Naltrexone
,20137766,Bioavailability,"Bioavailability compared with OTFC was significantly greater for all nasal fentanyl formulations (FPNS 132.4%, FChNS 154.1%, FChPNS 122.3%).","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),%,154.1,139718,DB00704,Naltrexone
,20137766,Bioavailability,"Bioavailability compared with OTFC was significantly greater for all nasal fentanyl formulations (FPNS 132.4%, FChNS 154.1%, FChPNS 122.3%).","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),%,122.3,139719,DB00704,Naltrexone
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,0.33,139720,DB00704,Naltrexone
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,0.17,139721,DB00704,Naltrexone
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,0.26,139722,DB00704,Naltrexone
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,1.5,139723,DB00704,Naltrexone
,32622946,half the maximal effect (EC50),"The PK/PD analysis revealed that the antiemetic effect was related to the plasma naldemedine concentration, with a half maximal effective concentration that produces half the maximal effect (EC50) of 3.51 ng/mL.","Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622946/),[ng] / [ml],3.51,144318,DB00704,Naltrexone
,6488691,plasma clearance,Kinetics of naltrexone estimated from the intravenous dose indicated a plasma clearance range of 3.1 to 3.4 l/min and a t 1/2 range of 1.7 to 3.7 hr.,Kinetics of a naltrexone sustained-release preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488691/),[l] / [min],3.1 to 3.4,147699,DB00704,Naltrexone
,6488691,t 1/2,Kinetics of naltrexone estimated from the intravenous dose indicated a plasma clearance range of 3.1 to 3.4 l/min and a t 1/2 range of 1.7 to 3.7 hr.,Kinetics of a naltrexone sustained-release preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488691/),h,1.7 to 3.7,147700,DB00704,Naltrexone
,21209242,t(first),"After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.08 to 0.25,147740,DB00704,Naltrexone
,21209242,t(max),"After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.50 to 1.00,147741,DB00704,Naltrexone
,21209242,"t(max) (t(max,ss))","After repeat dosing, median t(max) (t(max,ss)) was 0.50 to 2.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.50 to 2.00,147742,DB00704,Naltrexone
greater,3410891,recovery,The recovery of nalbuphine and naltrexone (internal standard) was greater than 90%.,Determination of nalbuphine by high-performance liquid chromatography with electrochemical detection: application to clinical samples from postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410891/),%,90,148229,DB00704,Naltrexone
,3410891,signal-to-noise ratio,"Although the limit of detection was 0.3 ng/ml based on a signal-to-noise ratio of 3, the reliable limit of quantitation was 1 ng/ml (coefficient of variation 12%) using 1 ml of plasma.",Determination of nalbuphine by high-performance liquid chromatography with electrochemical detection: application to clinical samples from postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410891/),,3,148230,DB00704,Naltrexone
,19715381,Cmax,"Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03 ng/mL; p<0.05).","Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[ng] / [ml],1.67,151020,DB00704,Naltrexone
,19715381,Cmax,"Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03 ng/mL; p<0.05).","Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[ng] / [ml],1.03,151021,DB00704,Naltrexone
,19715381,AUCinfinity,Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUCinfinity 14.5 vs 10.3 ng . h/mL).,"Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[h·ng] / [ml],14.5,151022,DB00704,Naltrexone
,19715381,AUCinfinity,Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUCinfinity 14.5 vs 10.3 ng . h/mL).,"Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[h·ng] / [ml],10.3,151023,DB00704,Naltrexone
,19944650,score at pain flare,Mean score at pain flare was 7.1.,"ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19944650/),,7.1,151241,DB00704,Naltrexone
,20150521,C(max),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[ng] / [ml],1.08,152668,DB00704,Naltrexone
,20150521,C(max),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[ng] / [ml],1.01,152669,DB00704,Naltrexone
,20150521,AUC(0-12),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],6.3,152670,DB00704,Naltrexone
,20150521,AUC(0-12),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],6.2,152671,DB00704,Naltrexone
,20150521,AUC(inf),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],9.14,152672,DB00704,Naltrexone
,20150521,AUC(inf),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],9.60,152673,DB00704,Naltrexone
,15363499,plasma concentrations,"The 25 wt.% coated rods provided in vitro release of 0.36 mg/day/rod, and in vivo release of 0.29 mg/day/rod over 6 months, and showed dose-dependent nalmefene plasma concentrations (one rod: 3.33 +/- 0.56 ng/ml, three rods: 10.19 +/- 2.31 ng/ml).",Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15363499/),[ng] / [ml],3.33,153499,DB00704,Naltrexone
,15363499,plasma concentrations,"The 25 wt.% coated rods provided in vitro release of 0.36 mg/day/rod, and in vivo release of 0.29 mg/day/rod over 6 months, and showed dose-dependent nalmefene plasma concentrations (one rod: 3.33 +/- 0.56 ng/ml, three rods: 10.19 +/- 2.31 ng/ml).",Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15363499/),ng,10.,153500,DB00704,Naltrexone
,22123184,terminal plasma elimination half-life,The mean terminal plasma elimination half-life of 6β-naltrexol was 11.1±2.4 hours.,"6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123184/),h,11.1,155698,DB00704,Naltrexone
,22123184,effective dose (ED(50) ),"6β-Naltrexol potently blocked morphine-induced slowing of gastrointestinal transit, with a median effective dose (ED(50) ) of ~3 mg.","6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123184/),mg,3,155699,DB00704,Naltrexone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),min,30,157028,DB00704,Naltrexone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),h,3,157029,DB00704,Naltrexone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),min,55,157030,DB00704,Naltrexone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),min,53,157031,DB00704,Naltrexone
,7365688,semen/plasma drug concentration ratio,"At 120 min, the semen/plasma drug concentration ratio was 14 and 11 for the 1 and 5 mg/kg doses, respectively.","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),,14,157032,DB00704,Naltrexone
,7365688,semen/plasma drug concentration ratio,"At 120 min, the semen/plasma drug concentration ratio was 14 and 11 for the 1 and 5 mg/kg doses, respectively.","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),,11,157033,DB00704,Naltrexone
,6422028,release rate,"Application of the methodology to a biodegradable copolymer naltrexone delivery system in three monkeys showed an initial release rate of 3-8% of the dose per day over the first 3-5 days followed by a slow, rather constant release rate of 1-3% per day from day 5 to the time of the last measurable plasma sample (36-43 days).",Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6422028/),[%] / [d],1-3,162346,DB00704,Naltrexone
,21685245,Unbound fractions,"Unbound fractions in human plasma for NAQ and NAP were 0.026 ± 0.019 and 0.85 ± 0.12, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),,0.026,166958,DB00704,Naltrexone
,21685245,Unbound fractions,"Unbound fractions in human plasma for NAQ and NAP were 0.026 ± 0.019 and 0.85 ± 0.12, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),,0.85,166959,DB00704,Naltrexone
,21685245,K(m),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),μM,15.8,166960,DB00704,Naltrexone
,21685245,K(m),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),μM,1.8,166961,DB00704,Naltrexone
,21685245,V(max),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[pM] / [min],192,166962,DB00704,Naltrexone
,21685245,V(max),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[pM] / [min],8.1,166963,DB00704,Naltrexone
,21685245,Intrinsic hepatic clearance,"Intrinsic hepatic clearance was estimated to be 13 and 5 ml · min(-1) · kg(-1) for NAQ and NAP, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[ml] / [kg·min],13,166964,DB00704,Naltrexone
,21685245,Intrinsic hepatic clearance,"Intrinsic hepatic clearance was estimated to be 13 and 5 ml · min(-1) · kg(-1) for NAQ and NAP, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[ml] / [kg·min],5,166965,DB00704,Naltrexone
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,85,167046,DB00704,Naltrexone
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,155,167047,DB00704,Naltrexone
,11752106,transit time,"After 0.1 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 110 +/- 41.0 min.",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,110,167048,DB00704,Naltrexone
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,98,167049,DB00704,Naltrexone
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,140,167050,DB00704,Naltrexone
,11752106,transit time,"After 0.3 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 108 +/- 59.6 min (P < 0.05 compared with placebo plus morphine).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,108,167051,DB00704,Naltrexone
,27933600,Cmax,"Following administration of FBSF doses of 200-1200 μg, mean Cmax values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19ng/mL, respectively.","Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[ng] / [ml],0.383,170876,DB00704,Naltrexone
,27933600,Cmax,"Following administration of FBSF doses of 200-1200 μg, mean Cmax values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19ng/mL, respectively.","Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[ng] / [ml],2.19,170877,DB00704,Naltrexone
,27933600,AUClast,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[ng] / [ml],3.001,170878,DB00704,Naltrexone
,27933600,AUClast,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[h·ng] / [ml],19.17,170879,DB00704,Naltrexone
,27933600,AUC∞,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[h·ng] / [ml],3.456,170880,DB00704,Naltrexone
,27933600,AUC∞,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[h·ng] / [ml],20.43,170881,DB00704,Naltrexone
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μM,28.,171538,DB00704,Naltrexone
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μ,1,171539,DB00704,Naltrexone
,3067620,area under the curve (AUC),"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),%·delta·min·t,5142,171540,DB00704,Naltrexone
,3067620,AUC,"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),bpm·min,1622,171541,DB00704,Naltrexone
,16239359,apparent half-lives,"The long apparent half-lives of naltrexone and 6beta-naltrexol (5-8 days) were attributed to the slow release of naltrexone (long-acting naltrexone exhibits absorption rate-limited elimination or ""flip-flop"" kinetics); elimination was not altered in subjects with hepatic impairment.",Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239359/),d,5-8,172816,DB00704,Naltrexone
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],4.54,174487,DB00704,Naltrexone
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],8.94,174488,DB00704,Naltrexone
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],17.80,174489,DB00704,Naltrexone
,15098800,area under the concentration versus time curve [AUC],"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],37.90,174490,DB00704,Naltrexone
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],5.60,174491,DB00704,Naltrexone
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],9.77,174492,DB00704,Naltrexone
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],19.3,174493,DB00704,Naltrexone
,15098800,AUC,"Dose-proportionality and linearity were confirmed after single doses (mean oxymorphone ER area under the concentration versus time curve [AUC] 4.54, 8.94, 17.80, and 37.90 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses, respectively) and at steady state (mean oxymorphone ER AUC 5.60, 9.77, 19.3, and 37.0 ng x hr/ml for 5-, 10-, 20-, and 40-mg doses every 12 hrs, respectively).",Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098800/),[h·ng] / [ml],37.0,174494,DB00704,Naltrexone
,22943926,Cmax,"The mean fentanyl Cmax and AUC0-∞ values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pg×h/ml, 4,489 pg×h/ml. respectively.",Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943926/),[pg] / [ml],948,177479,DB00704,Naltrexone
,22943926,Cmax,"The mean fentanyl Cmax and AUC0-∞ values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pg×h/ml, 4,489 pg×h/ml. respectively.",Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943926/),[h·pg] / [ml],"4,439",177480,DB00704,Naltrexone
,22943926,AUC0-∞,"The mean fentanyl Cmax and AUC0-∞ values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pg×h/ml, 4,489 pg×h/ml. respectively.",Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943926/),[h·pg] / [ml],"4,489",177481,DB00704,Naltrexone
exceeded,9726277,plasma concentrations,"After injection, NTX plasma concentrations exceeded a mean of 1 ng/ml for 21 days.",Sustained-release naltrexone for alcoholism treatment: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726277/),[ng] / [ml],1,181059,DB00704,Naltrexone
,19918182,maximum concentration,"After subcutaneous bolus dose administration, the median maximum concentration of fentanyl was 0.55 ng ml(-1) (range 0.28-0.87 ng ml(-1)), reached at a median time of 15 min (range 10-30 min).",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),[ng] / [ml],0.55,181497,DB00704,Naltrexone
,19918182,terminal half-life,The terminal half-life was 10.00 h (range 5.48-16.37 h).,Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,10.00,181498,DB00704,Naltrexone
,19918182,terminal half-life,"Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer (10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes.",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,10,181499,DB00704,Naltrexone
,19918182,terminal half-life,"Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer (10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes.",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,2.1,181500,DB00704,Naltrexone
,8852390,clearance,"Although the hemodialysis clearance of nalmefene glucuronide was 179.3 +/- 24.1 mL/min and its t1/2 was significantly reduced during dialysis to 5.2 +/- 2.3 hours, a dramatic rebound of nalmefene glucuronide concentrations of 75.7% was observed 7.7 +/- 5.4 hours after the end of hemodialysis.",The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852390/),[ml] / [min],179.3,181955,DB00704,Naltrexone
,8852390,t1/2,"Although the hemodialysis clearance of nalmefene glucuronide was 179.3 +/- 24.1 mL/min and its t1/2 was significantly reduced during dialysis to 5.2 +/- 2.3 hours, a dramatic rebound of nalmefene glucuronide concentrations of 75.7% was observed 7.7 +/- 5.4 hours after the end of hemodialysis.",The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852390/),h,5.2,181956,DB00704,Naltrexone
,6520774,limit of sensitivity,The procedure has a limit of sensitivity of 0.2 ng/mL of nalmefene using a 0.5-mL sample of plasma for analysis.,Nalmefene: radioimmunoassay for a new opioid antagonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520774/),[ng] / [ml],0.2,188355,DB00704,Naltrexone
,24107112,plasma concentrations,"After a single injection of naltrexone 200 and 400 mg, means (SD) of naltrexone plasma concentrations were .57 (.28) ng/ml and 1.5 (.8) ng/ml 30 days post-injection.","Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107112/),[ng] / [ml],.57,190095,DB00704,Naltrexone
,24107112,plasma concentrations,"After a single injection of naltrexone 200 and 400 mg, means (SD) of naltrexone plasma concentrations were .57 (.28) ng/ml and 1.5 (.8) ng/ml 30 days post-injection.","Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107112/),[ng] / [ml],1.5,190096,DB00704,Naltrexone
,18081355,AUC from time 0 to t(max'),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),[h·ng] / [ml],0.35,192212,DB00704,Naltrexone
,18081355,time to C(max),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),[h·ng] / [ml],0.35,192213,DB00704,Naltrexone
,18081355,time to C(max),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),h,0.75,192214,DB00704,Naltrexone
,18081355,time to C(max),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),h,0.78,192215,DB00704,Naltrexone
,15956985,t(1/2),The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing.,Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956985/),h,13.4,193356,DB00704,Naltrexone
,15956985,occupancy,High nalmefene occupancy (83-100%) persisted at 26 h after the dosings.,Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956985/),%,83-100,193357,DB00704,Naltrexone
,16740093,steady-state volume of distribution,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg],244.6,195175,DB00704,Naltrexone
,16740093,t1/2,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),min,47.04,195176,DB00704,Naltrexone
,16740093,clearance,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg·min],11.43,195177,DB00704,Naltrexone
,21502953,effective concentration 50,GSK1521498 had high affinity for human brain ORs (GSK1521498 effective concentration 50 = 7.10 ng ml(-1)) and there was a direct relationship between receptor occupancy (RO) and plasma concentrations of GSK1521498.,Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502953/),[ng] / [ml],7.10,200324,DB00704,Naltrexone
,25653563,area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t,"Exposure to hydrocodone after HC-ER 20 mg was similar in the fed and fasted states, as assessed by area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t; 316.14 versus 311.94 ng · h/mL); relative bioavailability (Frel) was 101.74%.","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],316.14,200806,DB00704,Naltrexone
,25653563,area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t,"Exposure to hydrocodone after HC-ER 20 mg was similar in the fed and fasted states, as assessed by area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t; 316.14 versus 311.94 ng · h/mL); relative bioavailability (Frel) was 101.74%.","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],311.94,200807,DB00704,Naltrexone
,25653563,relative bioavailability (Frel),"Exposure to hydrocodone after HC-ER 20 mg was similar in the fed and fasted states, as assessed by area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t; 316.14 versus 311.94 ng · h/mL); relative bioavailability (Frel) was 101.74%.","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),%,101.74,200808,DB00704,Naltrexone
,25653563,maximum plasma concentration (Cmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],28.86,200809,DB00704,Naltrexone
,25653563,maximum plasma concentration (Cmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],22.74,200810,DB00704,Naltrexone
,25653563,time to Cmax (tmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,6,200811,DB00704,Naltrexone
,25653563,time to Cmax (tmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,8,200812,DB00704,Naltrexone
,25653563,AUC0-t,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],878,200813,DB00704,Naltrexone
,25653563,AUC0-t,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],832,200814,DB00704,Naltrexone
,25653563,Frel,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),%,105,200815,DB00704,Naltrexone
,25653563,Cmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],51.8,200816,DB00704,Naltrexone
,25653563,Cmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],46.3,200817,DB00704,Naltrexone
,25653563,tmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,5.44,200818,DB00704,Naltrexone
,25653563,tmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,6.16,200819,DB00704,Naltrexone
,25653563,AUC0-t,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],"1,008",200820,DB00704,Naltrexone
,25653563,AUC0-t,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],832,200821,DB00704,Naltrexone
,25653563,Frel,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),%,120,200822,DB00704,Naltrexone
,25653563,Cmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],109,200823,DB00704,Naltrexone
,25653563,Cmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],46.3,200824,DB00704,Naltrexone
,25653563,tmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,2.43,200825,DB00704,Naltrexone
,25653563,tmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,6.16,200826,DB00704,Naltrexone
,3680580,elimination half-life,"Model-independent pharmacokinetic analysis of the plasma concentration-time data showed that nalmefene was rapidly absorbed and had an elimination half-life that ranged from seven to 15 hours (mean, 10.7 hr).",Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680580/),h,seven to 15,201292,DB00704,Naltrexone
,3680580,elimination half-life,"Model-independent pharmacokinetic analysis of the plasma concentration-time data showed that nalmefene was rapidly absorbed and had an elimination half-life that ranged from seven to 15 hours (mean, 10.7 hr).",Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680580/),h,10.7,201293,DB00704,Naltrexone
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,9,203445,DB00704,Naltrexone
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,4,203446,DB00704,Naltrexone
,8996532,plasma clearance rate,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],54 to 28,206813,DB00704,Naltrexone
,8996532,elimination half-life,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),min,6.9 to 12.2,206814,DB00704,Naltrexone
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],145,206815,DB00704,Naltrexone
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],94,206816,DB00704,Naltrexone
,23327357,Tmax,"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,180,209595,DB00704,Naltrexone
,23327357,C(max),"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ng] / [ml],1083.7,209596,DB00704,Naltrexone
,23327357,T(½),"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,496,209597,DB00704,Naltrexone
,23327357,T(max),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,180,209598,DB00704,Naltrexone
,23327357,C(max),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ng] / [ml],448.4,209599,DB00704,Naltrexone
,23327357,T(½),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,259,209600,DB00704,Naltrexone
,23327357,AUC₀₋₅₄₀ min,"The AUC₀₋₅₄₀ min for the MNTX-PC group was 5758.2 ± 1474.2 ngh/mL; for control, 1405.9 ± 447.8 ngh/mL.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ngh] / [ml],5758.2,209601,DB00704,Naltrexone
,23327357,AUC₀₋₅₄₀ min,"The AUC₀₋₅₄₀ min for the MNTX-PC group was 5758.2 ± 1474.2 ngh/mL; for control, 1405.9 ± 447.8 ngh/mL.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ngh] / [ml],1405.9,209602,DB00704,Naltrexone
,23327357,relative bioavailability,"Thus, the relative bioavailability after the oral administration of MNTX-PC was 410% compared to that of control.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),%,410,209603,DB00704,Naltrexone
,22717418,C(max),"The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although C(max) was ~16.5% lower.","Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22717418/),%,16.5,210871,DB00704,Naltrexone
,28421874,maximum plasma concentration,"Oxycodone was detected 8.0 ± 2.7-h postpatch administration, reaching a mean maximum plasma concentration of 3.41 ± 1.34 ng/ml at 49.3 ± 21.2 h.","Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421874/),[ng] / [ml],3.41,212221,DB00704,Naltrexone
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,72 to 108,214228,DB00704,Naltrexone
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,4-12,214229,DB00704,Naltrexone
,2839637,half-time of the terminal phase,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,96,214230,DB00704,Naltrexone
,17270058,Tmax,Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose.,Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270058/),h,12.0-16.0,215475,DB00704,Naltrexone
,17270058,t1/2,Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose.,Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270058/),h,10.6-11.0,215476,DB00704,Naltrexone
,30698833,Tmax,The addition of the absorption enhancer dodecyl maltoside (Intravail) increased Cmax by ∼3-fold and reduced the Tmax from 0.5 to 0.17 hours.,Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,0.5,219742,DB00704,Naltrexone
,30698833,Tmax,The addition of the absorption enhancer dodecyl maltoside (Intravail) increased Cmax by ∼3-fold and reduced the Tmax from 0.5 to 0.17 hours.,Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,0.17,219743,DB00704,Naltrexone
,30698833,half-life,"Despite these very rapid increases in plasma concentrations of naltrexone, its short half-life following intranasal administration (∼2.2 hours) could limit its usefulness as a rescue medication, particularly against longer-lived synthetic opioids.",Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,∼2.2,219744,DB00704,Naltrexone
,21084042,tmax,Median tmax values for FPNS ranged from 15 to 21 min post-dose and were dose-independent.,Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084042/),min,15 to 21,219894,DB00704,Naltrexone
,21084042,relative bioavailability,Mean relative bioavailability of FPNS to OTFC ranged from 103% to 163%.,Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084042/),%,103,219895,DB00704,Naltrexone
,21084042,relative bioavailability,Mean relative bioavailability of FPNS to OTFC ranged from 103% to 163%.,Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084042/),%,163,219896,DB00704,Naltrexone
,30977959,Renal,"Renal clearance decreased with reduced renal function (normal function 1.3 L/h; mild impairment 1.1 L/h; moderate impairment 1.0 L/h; severe impairment 0.5 L/h), and only 2.7% of naldemedine was removed by hemodialysis.","The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977959/),[l] / [h],1.3,220994,DB00704,Naltrexone
,30977959,Renal,"Renal clearance decreased with reduced renal function (normal function 1.3 L/h; mild impairment 1.1 L/h; moderate impairment 1.0 L/h; severe impairment 0.5 L/h), and only 2.7% of naldemedine was removed by hemodialysis.","The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977959/),,1,220995,DB00704,Naltrexone
,17470643,K(i),ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM).,"Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),nM,0.26,223016,DB00704,Naltrexone
,17470643,ED(50),"ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c.","Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),[mg] / [kg],3,223017,DB00704,Naltrexone
,905632,first pass effect,The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),%,79.6,225306,DB00704,Naltrexone
,905632,first pass effect,The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),%,78.0,225307,DB00704,Naltrexone
,905632,apparent chronic release rate (ACRR),From our pharmacokinetic data an apparent chronic release rate (ACRR) for a sustained release preparation of naltrexone was calculated as 11.8 microgram/kg/hr.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),[μg] / [h·kg],11.8,225308,DB00704,Naltrexone
,19915709,AUC(0-infinity),"Regimens A and B had bioequivalent systemic exposure parameters (B/A [90% CI]: AUC(0-infinity)108.4 [103.4, 113.7], AUC(0-last) 106.1 [100.7, 111.7], and C(max) 92.3 [83.2, 102.4]).",Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),,108.4,229124,DB00704,Naltrexone
,19915709,AUC(0-last),"Regimens A and B had bioequivalent systemic exposure parameters (B/A [90% CI]: AUC(0-infinity)108.4 [103.4, 113.7], AUC(0-last) 106.1 [100.7, 111.7], and C(max) 92.3 [83.2, 102.4]).",Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),,106.1,229125,DB00704,Naltrexone
,19915709,C(max),"Regimens A and B had bioequivalent systemic exposure parameters (B/A [90% CI]: AUC(0-infinity)108.4 [103.4, 113.7], AUC(0-last) 106.1 [100.7, 111.7], and C(max) 92.3 [83.2, 102.4]).",Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),,92.3,229126,DB00704,Naltrexone
,19915709,time to C(max),Median time to C(max) was 45 minutes for regimen A and 60 minutes for regimens B and C.,Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),min,45,229127,DB00704,Naltrexone
,19915709,time to C(max),Median time to C(max) was 45 minutes for regimen A and 60 minutes for regimens B and C.,Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),min,60,229128,DB00704,Naltrexone
,19806909,t1/2alpha,"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.26,230137,DB00704,Naltrexone
,19806909,t1/2beta,"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,4.77,230138,DB00704,Naltrexone
,19806909,C(max),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],81.65,230139,DB00704,Naltrexone
,19806909,t(peak),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.27,230140,DB00704,Naltrexone
,19806909,CL(s),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [h·kg],1.20,230141,DB00704,Naltrexone
,19806909,V/F(c),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [kg],1.94,230142,DB00704,Naltrexone
,19806909,AUC(0-t),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[h·ng] / [ml],166.82,230143,DB00704,Naltrexone
,19806909,t1/2alpha,"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.19,230144,DB00704,Naltrexone
,19806909,t1/2beta,"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,5.79,230145,DB00704,Naltrexone
,19806909,C(max),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],79.82,230146,DB00704,Naltrexone
,19806909,t(peak),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.18,230147,DB00704,Naltrexone
,19806909,CL(s),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [h·kg],1.12,230148,DB00704,Naltrexone
,19806909,V/F(c),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [kg],2.10,230149,DB00704,Naltrexone
,19806909,AUC(0-t),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[h·ng] / [ml],173.23,230150,DB00704,Naltrexone
,19806909,peak,"In the course of multiple administration, the peak and valley concentration of plasma 6beta-naltrexol were (79.03 +/- 10.3) and (1.50 +/- 0.93) ng x mL(-1), respectively.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],79.03,230151,DB00704,Naltrexone
,19806909,valley concentration,"In the course of multiple administration, the peak and valley concentration of plasma 6beta-naltrexol were (79.03 +/- 10.3) and (1.50 +/- 0.93) ng x mL(-1), respectively.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],1.50,230152,DB00704,Naltrexone
,16861092,T,Median T was between 35 and 45 minutes after FEBT administration.,"Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861092/),min,35 and 45,231486,DB00704,Naltrexone
,16861092,AUC(0-Tmax'),AUC(0-Tmax') ranged from 0.09 ng x h/mL with the 100-microg dose to 0.52 ng x h/mL with the 800-microg dose.,"Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861092/),[h·ng] / [ml],0.09,231487,DB00704,Naltrexone
,16861092,AUC(0-Tmax'),AUC(0-Tmax') ranged from 0.09 ng x h/mL with the 100-microg dose to 0.52 ng x h/mL with the 800-microg dose.,"Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861092/),[h·ng] / [ml],0.52,231488,DB00704,Naltrexone
,17319131,peak plasma concentration (C(max)),"Carfentanil was rapidly absorbed following administration, with the peak plasma concentration (C(max)) at 13.8 min.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),min,13,232829,DB00704,Naltrexone
,17319131,C(max),Naltrexone was readily absorbed and reached C(max) at 23.4 +/- 16.8 min after administration.,Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),min,23.4,232830,DB00704,Naltrexone
,17319131,half-life,"Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),h,7.7,232831,DB00704,Naltrexone
,17319131,half-life,"Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),h,3.7,232832,DB00704,Naltrexone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,8.5,233624,DB00704,Naltrexone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,16.2,233625,DB00704,Naltrexone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,7.6,233626,DB00704,Naltrexone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,9.1,233627,DB00704,Naltrexone
,17539894,t1/2,"Small bowel, ascending colon half-life (in pharmacokinetics) (t1/2), and colonic geometric centre (8, 24, 48 h) were assessed by scintigraphy.",Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17539894/),h,8,237806,DB00704,Naltrexone
,17539894,t1/2,"Small bowel, ascending colon half-life (in pharmacokinetics) (t1/2), and colonic geometric centre (8, 24, 48 h) were assessed by scintigraphy.",Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17539894/),h,24,237807,DB00704,Naltrexone
,17539894,t1/2,"Small bowel, ascending colon half-life (in pharmacokinetics) (t1/2), and colonic geometric centre (8, 24, 48 h) were assessed by scintigraphy.",Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17539894/),h,48,237808,DB00704,Naltrexone
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00704,Naltrexone
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00704,Naltrexone
,24071566,ED₅₀,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (ED₅₀ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00704,Naltrexone
,8520812,area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24),"Although naltrexone did not qualitatively alter the concentration-time curve for controlled-release morphine, the area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24) was significantly greater (p < 0.01) for morphine given with naltrexone (265 ng x h/ml) than for morphine given alone (215 ng x h/ml).",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[h·ng] / [ml],265,243028,DB00704,Naltrexone
,8520812,area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24),"Although naltrexone did not qualitatively alter the concentration-time curve for controlled-release morphine, the area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24) was significantly greater (p < 0.01) for morphine given with naltrexone (265 ng x h/ml) than for morphine given alone (215 ng x h/ml).",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[h·ng] / [ml],215,243029,DB00704,Naltrexone
,8520812,apparent absorption half-life,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),h,0.94-0.58,243030,DB00704,Naltrexone
,8520812,Cmax,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[ng] / [ml],28.17,243031,DB00704,Naltrexone
,8520812,Cmax,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[ng] / [ml],32.26,243032,DB00704,Naltrexone
,15726882,Cmax,The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ng] / [ml],255,243889,DB00704,Naltrexone
,15726882,Cmax,The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ng] / [ml],206,243890,DB00704,Naltrexone
,15726882,Cmax,The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ng] / [ml],9 - 44,243891,DB00704,Naltrexone
,15726882,Tmax,Tmax before and after dialysis plates remain unchanged as healthy subjects (approximately 1h).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),h,1,243892,DB00704,Naltrexone
,15726882,clearance,"With regard to dialysability, a high dialyzer extraction ratio averating 30 % was found with a low dialysis clearance of 58.70+/-17 mL/min.",Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ml] / [min],58.70,243893,DB00704,Naltrexone
,15726882,amount removed,The amount removed by dialysis is only 1.27 mg.,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),mg,1.27,243894,DB00704,Naltrexone
,3943269,t1/2,"The plasma concentration-time data were best fit with a triexponential equation, and the terminal elimination phase had a harmonic mean t1/2 of 8 to 9 hours.",Nalmefene: intravenous safety and kinetics of a new opioid antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943269/),h,8 to 9,245062,DB00704,Naltrexone
,762657,serum half-life during the elimination phase,Serum levels of both naloxone and naltrexone fell rapidly; serum half-life during the elimination phase was 71.2 +/- 8.9 min (mean +/- S.E.) for naloxone and 85.1 +/- 9.0 min (mean +/- S.E.) for naltrexone.,Pharmacokinetics of naloxone and naltrexone in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/762657/),min,71.2,246187,DB00704,Naltrexone
,762657,serum half-life during the elimination phase,Serum levels of both naloxone and naltrexone fell rapidly; serum half-life during the elimination phase was 71.2 +/- 8.9 min (mean +/- S.E.) for naloxone and 85.1 +/- 9.0 min (mean +/- S.E.) for naltrexone.,Pharmacokinetics of naloxone and naltrexone in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/762657/),min,85.1,246188,DB00704,Naltrexone
,19915714,C(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[ng] / [ml],1.70,250435,DB00704,Naltrexone
,19915714,C(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[ng] / [ml],1.97,250436,DB00704,Naltrexone
,19915714,AUC(0-6),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[h·ng] / [ml],4.46,250437,DB00704,Naltrexone
,19915714,AUC(0-6),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[h·ng] / [ml],6.81,250438,DB00704,Naltrexone
,19915714,t(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),min,50,250439,DB00704,Naltrexone
,19915714,t(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),min,30,250440,DB00704,Naltrexone
>,22642416,water solubility,"None of the drugs were highly lipophilic, showing high water solubility (> 45 mM) and low distribution into octanol (log D7.4 < 2).","Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642416/),mM,45,250539,DB00704,Naltrexone
<,22642416,log D7.4,"None of the drugs were highly lipophilic, showing high water solubility (> 45 mM) and low distribution into octanol (log D7.4 < 2).","Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642416/),,2,250540,DB00704,Naltrexone
,23497761,Cmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),[ng] / [ml],0.81,254914,DB00704,Naltrexone
,23497761,Cmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),[ng] / [ml],0.61,254915,DB00704,Naltrexone
,23497761,Tmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),h,1.5,254916,DB00704,Naltrexone
,23497761,Tmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),h,2.0,254917,DB00704,Naltrexone
,23497761,Systemic bioavailability,Systemic bioavailability was also greater with FSS than with OTFC (approximately 76% vs 51%).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),%,76,254918,DB00704,Naltrexone
,23497761,Systemic bioavailability,Systemic bioavailability was also greater with FSS than with OTFC (approximately 76% vs 51%).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),%,51,254919,DB00704,Naltrexone
,16499489,apparent elimination half-lives,Mean apparent elimination half-lives for naltrexone and 6beta-naltrexol ranged from 5 to 7 days.,Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16499489/),d,5 to 7,255998,DB00704,Naltrexone
,32700999,maximum observed concentration,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),[ng] / [ml],35.1,258336,DB00704,Naltrexone
,32700999,maximum observed concentration,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),[ng] / [ml],33.5,258337,DB00704,Naltrexone
,32700999,terminal half-life,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),h,7.92,258338,DB00704,Naltrexone
,32700999,terminal half-life,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),h,7.09,258339,DB00704,Naltrexone
,20637968,Plasma C(max),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[pg] / [ml],579,262116,DB00704,Naltrexone
,20637968,Plasma C(max),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[pg] / [ml],584,262117,DB00704,Naltrexone
,20637968,AUC(0-t),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·pg] / [ml],1811,262118,DB00704,Naltrexone
,20637968,AUC(0-t),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·pg] / [ml],1954,262119,DB00704,Naltrexone
,20637968,AUC(0-t),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·ng] / [ml],163,262120,DB00704,Naltrexone
,20637968,AUC(0-t),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·ng] / [ml],174,262121,DB00704,Naltrexone
,20637968,C(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[ng] / [ml],24.5,262122,DB00704,Naltrexone
,20637968,C(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[ng] / [ml],7.7,262123,DB00704,Naltrexone
,20637968,T(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),h,2.00,262124,DB00704,Naltrexone
,20637968,T(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),h,7.03,262125,DB00704,Naltrexone
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],125.4,262297,DB00704,Naltrexone
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],57.2,262298,DB00704,Naltrexone
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],2561,262299,DB00704,Naltrexone
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],1095,262300,DB00704,Naltrexone
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,5.0,262301,DB00704,Naltrexone
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,8.0,262302,DB00704,Naltrexone
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.8,262303,DB00704,Naltrexone
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.4,262304,DB00704,Naltrexone
,3981418,sensitivities,"Sensitive reversed-phase HPLC assays with electrochemical detection, developed to quantify naltrexone, 6 beta-naltrexol, and their conjugates in biological fluids, provided assay sensitivities of 2-14 ng/mL in plasma, urine, and bile.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ng] / [ml],2-14,265314,DB00704,Naltrexone
,3981418,P,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,5,265315,DB00704,Naltrexone
,3981418,half-lives,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,5,265316,DB00704,Naltrexone
,3981418,half-lives,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,47,265317,DB00704,Naltrexone
,3981418,total,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ml] / [min],1043,265318,DB00704,Naltrexone
,3981418,renal clearances,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ml] / [min],72,265319,DB00704,Naltrexone
,3981418,renal clearance,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),,85,265320,DB00704,Naltrexone
,30992306,half-life,"The addition of naltrexone [17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one], another μ-receptor antagonist, which has a reported half-life of 3 1/2 hours, may extend the available time to receive medical treatment.",Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30992306/),h,3 1/2,266989,DB00704,Naltrexone
,12401350,flow-rate,"The procedure was performed using a Phenomenex Prodigy ODS-2, 5 microm, 150x3.2 mm analytical column and 50 mM potassium acetate buffer, with 11% methanol as organic modifier at pH* 4.5 at a flow-rate of 0.5 ml/min.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ml] / [min],0.5,268919,DB00704,Naltrexone
,12401350,detection potential,The detection potential was 700 mV.,Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),m,700,268920,DB00704,Naltrexone
,12401350,limit of quantification (LOQ),"The lower limit of detection (LOD) and limit of quantification (LOQ) were found to be 2.0 and 5.0 ng/ml, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],5.0,268921,DB00704,Naltrexone
,12401350,Recovery,Recovery of the drug from plasma was in the region of 94%.,Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),%,94,268922,DB00704,Naltrexone
,12401350,C(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],110,268923,DB00704,Naltrexone
,12401350,C(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],287,268924,DB00704,Naltrexone
,12401350,t(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),min,16.7,268925,DB00704,Naltrexone
,12401350,t(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),min,20.0,268926,DB00704,Naltrexone
,9024170,systemic clearance,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),[l] / [h·kg],0.61,269910,DB00704,Naltrexone
,9024170,systemic clearance,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),[l] / [h·kg],0.90,269911,DB00704,Naltrexone
,9024170,terminal elimination half-life,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),h,10.5,269912,DB00704,Naltrexone
,9024170,terminal elimination half-life,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),h,8.0,269913,DB00704,Naltrexone
,31278694,Cmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[ng] / [ml],44.78,272649,DB00704,Naltrexone
,31278694,Cmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[ng] / [ml],33.30,272650,DB00704,Naltrexone
,31278694,Tmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),min,30,272651,DB00704,Naltrexone
,31278694,AUC0-∞,The overall morphine exposure (AUC0-∞) was similar for fed (440.6 ng · h/ml) vs. fasted conditions (395.1 ng · h/ml).,"A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[h·ng] / [ml],440.6,272652,DB00704,Naltrexone
,31278694,AUC0-∞,The overall morphine exposure (AUC0-∞) was similar for fed (440.6 ng · h/ml) vs. fasted conditions (395.1 ng · h/ml).,"A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[h·ng] / [ml],395.1,272653,DB00704,Naltrexone
,26804639,bioavailability,"In the single-dose study, the 2 formulations exhibited comparable bioavailability of 46% to 51% that was independent of dose, with a single buprenorphine peak concentration from each BBUP dose occurring at 2.5 to 3 hours.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,46,273236,DB00704,Naltrexone
,26804639,bioavailability,"In the single-dose study, the 2 formulations exhibited comparable bioavailability of 46% to 51% that was independent of dose, with a single buprenorphine peak concentration from each BBUP dose occurring at 2.5 to 3 hours.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,51,273237,DB00704,Naltrexone
,26804639,Cmax,The mean buprenorphine Cmax across the doses ranged from 0.17 ng/mL for the 75-µg dose to 1.43 ng/mL for the 1200-µg dose.,Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),[ng] / [ml],0.17,273238,DB00704,Naltrexone
,26804639,Cmax,The mean buprenorphine Cmax across the doses ranged from 0.17 ng/mL for the 75-µg dose to 1.43 ng/mL for the 1200-µg dose.,Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),[ng] / [ml],1.43,273239,DB00704,Naltrexone
,26804639,absolute bioavailability,"The absolute bioavailability of BBUP was 46% to 51% across a 16-fold dose range, with dose-proportional increases in systemic exposure.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,46,273240,DB00704,Naltrexone
,26804639,absolute bioavailability,"The absolute bioavailability of BBUP was 46% to 51% across a 16-fold dose range, with dose-proportional increases in systemic exposure.",Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804639/),%,51,273241,DB00704,Naltrexone
,19874646,recoveries,The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),%,69.2,273880,DB00704,Naltrexone
,19874646,recoveries,The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),%,32.0,273881,DB00704,Naltrexone
,19874646,AUC(0-24),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),[ng] / [h·ml],0.303,273882,DB00704,Naltrexone
,19874646,C(max),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),[ng] / [ml],0.139,273883,DB00704,Naltrexone
,19874646,T(max),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),h,0.5,273884,DB00704,Naltrexone
